News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Hong Kong Institute of Biotechnology To Open A New GMP Multipurpose Purification Pilot Plant

10/19/2005 5:08:55 PM

To further enhance Hong Kong's strong position in biotechnology research and product development, the Hong Kong Institute of Biotechnology (HKIB), a wholly owned subsidiary of the Chinese University of Hong Kong, had designed and constructed a new biotechnology and plasma-derived therapeutics downstream pilot GMP facility which is funded by the Innovation and Technology Programme of The Innovation and Technology Fund of the Hong Kong SAR Government. The new Plant serves as a multipurpose protein purification platform for the production of clinical grade materials with built-in biopharmaceutical manufacturing systems in accordance with Hong Kong and China Good Manufacturing Practice (GMP) requirements. "The new Plant is an important element in our goal to make Hong Kong the city of biotechnology," said Prof. Walter Ho, Managing Director of HKIB. "By continuing to support this critical industry, from initial research to manufacturing, we are ensuring that the industry continues to grow and develop." The new Plant is designed to enhance HKIB's multifaceted relationships with industry, academic and government institutes. It also permits acceleration of basic and applied product research in partnership with industry such as the project sponsor, Advantek Biologics Limited, which will make use of the Plant to develop plasma-derived therapeutics using technologies licensed from Amersham Biosciences (a business unit of General Electric Company, NYSE: GE), New York Blood Center and Asahi Kasei Pharma Corporation (TSE: 3407). The targeted markets for these products include a wide spectrum of diseases such as primary immune deficiency, lupus, Hepatitis B and rabies. According to Dr. Bing Lou Wong, CEO of Advantek, it is the first step of a series of initiatives jointly undertaken in Hong Kong and China to help alleviate the severe shortage of the US$8 billion global plasma therapeutic market. CUHK and The Board of Directors of HKIB are grateful that the Hong Kong SAR Government continues to support the vision of HKIB and expand its missions. HKIB will continue to make positive impacts on the industrial front for Hong Kong and new efforts to promote and attract biotechnology R&D and investments.

comments powered by Disqus